- Home
- ENSC vs NVVE Comparison
ENSC vs NVVE Comparison
Compare ENSC & NVVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENSC
- NVVE
- Stock Information
- Founded
- ENSC 2003
- NVVE 1996
- Country
- ENSC United States
- NVVE United States
- Employees
- ENSC N/A
- NVVE N/A
- Industry
- ENSC Biotechnology: Pharmaceutical Preparations
- NVVE Oil Refining/Marketing
- Sector
- ENSC Health Care
- NVVE Energy
- Exchange
- ENSC Nasdaq
- NVVE Nasdaq
- Market Cap
- ENSC 5.5M
- NVVE 5.5M
- IPO Year
- ENSC N/A
- NVVE N/A
- Fundamental
- Price
- ENSC $2.13
- NVVE $0.85
- Analyst Decision
- ENSC
- NVVE
- Analyst Count
- ENSC 0
- NVVE 0
- Target Price
- ENSC N/A
- NVVE N/A
- AVG Volume (30 Days)
- ENSC 84.7K
- NVVE 1.7M
- Earning Date
- ENSC 08-13-2025
- NVVE 08-12-2025
- Dividend Yield
- ENSC N/A
- NVVE N/A
- EPS Growth
- ENSC N/A
- NVVE N/A
- EPS
- ENSC N/A
- NVVE N/A
- Revenue
- ENSC $6,224,081.00
- NVVE $5,440,777.00
- Revenue This Year
- ENSC N/A
- NVVE $892.33
- Revenue Next Year
- ENSC $1,381.48
- NVVE N/A
- P/E Ratio
- ENSC N/A
- NVVE N/A
- Revenue Growth
- ENSC 256.35
- NVVE N/A
- 52 Week Low
- ENSC $1.62
- NVVE $0.82
- 52 Week High
- ENSC $14.67
- NVVE $8.80
- Technical
- Relative Strength Index (RSI)
- ENSC 45.62
- NVVE 43.88
- Support Level
- ENSC $1.97
- NVVE $0.86
- Resistance Level
- ENSC $2.40
- NVVE $0.98
- Average True Range (ATR)
- ENSC 0.17
- NVVE 0.10
- MACD
- ENSC -0.00
- NVVE -0.00
- Stochastic Oscillator
- ENSC 37.21
- NVVE 28.73
About ENSC Ensysce Biosciences Inc.
Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.
About NVVE Nuvve Holding Corp.
Nuvve Holding Corp is accelerating the electrification of transportation through its proprietary vehicle-to-grid (V2G) technology. It helps to support the integration of renewable energy sources, including solar and wind. Its Grid Integrated Vehicle (GIV) platform is refueling the next generation of electric vehicle fleets through bidirectional charging solutions. It has a geographic presence in the United States, the United Kingdom, and Denmark, of which it generates the majority of its revenue in the United States.